Status:
RECRUITING
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborating Sponsors:
Chinese Academy of Medical Sciences, Fuwai Hospital
Chinese Academy of Medical Sciences
Conditions:
Coronary Artery Disease
Ischemic Mitral Regurgitation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolate...
Eligibility Criteria
Inclusion
- Fully informed and voluntarily signed informed consent;
- Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )
Exclusion
- Symptomatic hypotension and/or a SBP \< 100 mmHg at screening; 2.Estimated GFR \< 30 mL/min/1.73m2; 3.Serum potassium \> 5 mmol/L at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.
Key Trial Info
Start Date :
June 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT06917664
Start Date
June 5 2025
End Date
June 1 2027
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China National Center for Cardiovascular Diseases
Beijing, Beijing Municipality, China, 100037